Trials / Unknown
UnknownNCT05103306
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
Long-term Effectiveness and Safety of Empagliflozin-based Quadruple Oral Antidiabetic Agents Therapy Compared to Basal Insulin-based Combination Therapy in Patients With Type 2 Diabetes
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Chungbuk National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical practice.
Detailed description
This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 25 MG | Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor |
| DRUG | INS | Basal insulin add on the background OADs |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-11-02
- Last updated
- 2022-07-20
Source: ClinicalTrials.gov record NCT05103306. Inclusion in this directory is not an endorsement.